an2728 profile

crisaborole: NSAID, Dermatologic Agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

crisaborole : A member of the class of benzoxaboroles that is 5-hydroxy-1,3-dihydro-2,1-benzoxaborole in which the phenolic hydrogen has been replaced by a 4-cyanophenyl group. A phosphodiesterase 4 inhibitor that is used for treatment of mild to moderate atopic dermatitis in children and adults. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	44591583
CHEMBL ID	484785
CHEBI ID	134677
SCHEMBL ID	595261
MeSH ID	M0538515

Synonym
crisaborole topical ointment 2%
906673-24-3
an2728
an 2728
CHEBI:134677 ,
4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy]benzonitrile
crisaborole
an-2728 ,
eucrisa
CHEMBL484785 ,
bdbm50277665
4-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yloxy)benzonitrile
4-((1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)oxy)benzonitrile
AKOS016005425
HY-10978
CS-1057
NCGC00345792-01
5-(4-cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole
q2r47hgr7p ,
unii-q2r47hgr7p
benzonitrile, 4-((1,3-dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy)-
4-((1-hydroxy-1,3-dihydrobenzo(c)(1,2)oxaborol-6-yl)oxy)benzonitrile
crisaborole [usan:inn]
4-[(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy]benzonitrile
5-(4-cyanophenoxy)-1-hydroxy-2,1-benzoxaborole
USZAGAREISWJDP-UHFFFAOYSA-N
SCHEMBL595261
DB05219
crisaborole [usan]
crisaborole [inn]
crisaborole [mi]
crisaborole [who-dd]
crisaborole [orange book]
AC-30331
c14h10bno3
4-[(1-hydroxy-3h-2,1-benzoxaborol-5-yl)oxy]benzonitrile
staquis
gtpl9151
compound 5b [pmid: 19303290]
mfcd17169940
DTXSID10238231
EX-A1087
AS-70551
C90670
D10873
crisaborole (usan/inn)
eucrisa (tn)
NCGC00345792-02
pf-06930164
crisaborole, >=98% (hplc)
4-((1-hydroxy-1,3-dihydrobenzo-[c][1,2]oxaborol-5-yl)oxy)benzonitrile
crisaborole(an-2728)
FT-0767999
906673-25-4
Q21098894
1073669-75-6
BCP08677
SB16802
CCG-266972
NCGC00345792-04
C90571
4-[(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)oxy]benzonitrile
SY113089
crisaborole (an2728)
S5014
TQP0866
F51164
crisaborole;4-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yloxy)benzonitrile;an-2728
4-((1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy)benzonitrile
crisaborolum
crisaborol
compound 5b (pmid: 19303290)
d11ah06
EN300-7359142

Excerpt	Reference	Relevance
" Safety assessments included adverse events (AEs), laboratory parameters, and vital signs."	( Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study. Chanda, S; Tom, WL; Van Syoc, M; Zane, LT, )	0.13
" Treatment-related adverse events were infrequent and mild to moderate in severity."	( Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. Blumenthal, RL; Boguniewicz, M; Call, RS; Eichenfield, LF; Forsha, DW; Hebert, AA; Hughes, MH; Lebwohl, MG; Paller, AS; Rees, WC; Simpson, EL; Spellman, MC; Stein Gold, LF; Tom, WL; Zaenglein, AL; Zane, LT, 2016)	0.43
" Adverse events (AEs), including treatment-emergent AEs (TEAEs), and serious AEs were analyzed."	( Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. Call, RS; Eichenfield, LF; Forsha, DW; Fowler, J; Hebert, AA; Spellman, M; Stein Gold, LF; Tschen, E; Van Syoc, M; Zane, LT, 2017)	0.46
" The most common treatment-related adverse event was application site pain."	( Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups. Alexis, AF; Callender, VD; Desai, SR; Lebwohl, MG; Paller, AS; Ports, WC; Stein Gold, LF; Tallman, AM; Tan, H; Zielinski, MA, 2019)	0.51
"Across races and ethnicities, crisaborole demonstrated efficacy for the treatment of mild-to-moderate atopic dermatitis, with a low frequency of treatment-related adverse events."	( Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups. Alexis, AF; Callender, VD; Desai, SR; Lebwohl, MG; Paller, AS; Ports, WC; Stein Gold, LF; Tallman, AM; Tan, H; Zielinski, MA, 2019)	0.51
" Treatment-emergent adverse events (TEAEs) were reported for 88 (64."	( Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1). Cha, A; Gower, R; Lynde, C; Ports, WC; Purohit, V; Schlessinger, J; Shepard, JS; Su, JC; Takiya, L; Vlahos, B; Werth, JL; Zang, C, 2020)	0.56
" Fewer than 1 in 25 patients experienced each side effect where crisaborole was applied."	( Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1). Cha, A; Gower, R; Lynde, C; Ports, WC; Purohit, V; Schlessinger, J; Shepard, JS; Su, JC; Takiya, L; Vlahos, B; Werth, JL; Zang, C, 2020)	0.56
" Treatment-related adverse events were mild/moderate."	( A phase I, randomized, double-blind study to assess the safety, tolerability and efficacy of the topical RORC2 inverse agonist PF-06763809 in participants with mild-to-moderate plaque psoriasis. Banfield, C; Beaumont, K; Berger, Z; Berstein, G; Dowty, H; Garcet, S; Hamscho, R; Kieras, E; Kroencke, U; Krueger, JG; Li, G; Oemar, B; Samuel, A; von Mackensen, Y; Wigger-Alberti, W; Yeoh, T; Zhang, Y, 2021)	0.62
" The primary endpoint was change from baseline in total sign score (TSS) in crisaborole- or vehicle-treated target lesions on day 15, and secondary endpoints included change from baseline in Investigator's Static Global Assessment (ISGA) and pruritic assessments (Cohort 1: peak pruritus numeric rating scale [NRS]; Cohort 2: Itch Severity Scale Self-Report and Caregiver-Reported Itch Severity NRS) and incidence of treatment-emergent adverse events (TEAEs)."	( A phase 2b, randomized, double-blind, multicenter, vehicle-controlled study to assess the efficacy and safety of two crisaborole regimens in Japanese patients aged 2 years and older with mild-to-moderate atopic dermatitis. Fujita, K; Graham, D; Moriwaki, S; Yagi, M; Yoshida, M, 2021)	0.62
" This systematic review is intended to synthesize the clinical trial literature and concisely report the updated safety and adverse effects of topical medications used to treat atopic dermatitis in children."	( Safety of topical medications in the management of paediatric atopic dermatitis: An updated systematic review. Hwang, A; Lio, P; Miller, C; Zhao, S, 2023)	0.91
" Safety data was well reported in tacrolimus trials with the most frequently reported adverse events being burning sensation, pruritus and cutaneous infections."	( Safety of topical medications in the management of paediatric atopic dermatitis: An updated systematic review. Hwang, A; Lio, P; Miller, C; Zhao, S, 2023)	0.91
"Data discussed here support the use of steroid-sparing medications (tacrolimus, pimecrolimus, crisaborole, delgocitinib) as safe options with minimal adverse events for managing paediatric AD, although a larger number of TCI studies reported burning and pruritus compared to TCS studies."	( Safety of topical medications in the management of paediatric atopic dermatitis: An updated systematic review. Hwang, A; Lio, P; Miller, C; Zhao, S, 2023)	0.91
" Safety was assessed using rates of treatment emergent adverse events, serious adverse events, and clinically significant changes in vital signs and clinical laboratory parameters."	( Efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged ≥2 years with mild-to-moderate atopic dermatitis. Chen, Y; Cheng, H; Kobayashi, M; Liu, S; Ma, L; Qian, Q; Tao, X; Zhang, J; Zhang, L; Zhou, Y, 2023)	0.91

Excerpt	Reference	Relevance
"Adolescent patients aged 12 to 17 years with treatable AD lesions involving ≥ 10% to ≤ 35% body surface area (BSA) were enrolled into a phase 2a, open-label study comprising pharmacokinetic (PK), safety, tolerability, and efficacy assessments."	( Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study. Chanda, S; Tom, WL; Van Syoc, M; Zane, LT, )	0.13

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" All dosing regimens produced dose-related improvements in ADSI as well as in all 5 component signs and symptoms of AD (erythema, excoriation, exudation, lichenification, and pruritus)."	( A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis. Hughes, MH; Spellman, MC; Spelman, L; Stein Gold, LF; Zane, LT, 2015)	0.42
" Crisaborole topical ointment, 2% was applied twice daily to affected areas for 28 days, with dosage based on baseline treatable BSA."	( Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study. Chanda, S; Tom, WL; Van Syoc, M; Zane, LT, )	0.13
" The 2% strength appeared to be the superior dosing regimen."	( 2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis. Cheape, AC; Murrell, DF, 2017)	0.46
"We analyzed the medical records of 77 AD patients who received dupilumab according to standard dosing and had at least one documented follow-up visit."	( Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records. Ganesan, AK; Grando, SA; Kraus, CN; Patel, KG; Wang, C, 2020)	0.56

Role	Description
phosphodiesterase IV inhibitor	An EC 3.1.4.53 (3',5'-cyclic-AMP phosphodiesterase) inhibitor that specifically blocks the action of phosphodiesterase IV.
antipsoriatic	A drug used to treat psoriasis.
non-steroidal anti-inflammatory drug	An anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
benzoxaborole	Any organic heterobicyclic compound that consists of an oxoborole ring that is ortho-fused to a benzene ring.
aromatic ether	Any ether in which the oxygen is attached to at least one aryl substituent.
nitrile	A compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Fumarate hydratase	Homo sapiens (human)	Potency	37.2212	0.0030	8.7949	48.0869	AID1347053
EWS/FLI fusion protein	Homo sapiens (human)	Potency	31.7859	0.0013	10.1577	42.8575	AID1259253; AID1259255
polyprotein	Zika virus	Potency	37.2212	0.0030	8.7949	48.0869	AID1347053
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	39.8107	0.0096	10.5250	35.4813	AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)	IC50 (µMol)	3,630.0000	0.0000	1.7767	9.2000	AID1756218
cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)	IC50 (µMol)	56,100.0000	0.0000	1.1843	9.6140	AID1756222
cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)	IC50 (µMol)	0.2863	0.0000	1.0680	10.0000	AID1406487; AID1720007; AID349551; AID349562
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	Homo sapiens (human)	IC50 (µMol)	2,803.0500	0.2300	2.5105	10.0000	AID1756215; AID349550
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)	IC50 (µMol)	17,900.0000	0.0000	2.1417	9.2000	AID1756216
cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)	IC50 (µMol)	10.1796	0.0000	1.1040	10.0000	AID1406488; AID1406489; AID1720007; AID1756184; AID1756221; AID349551; AID349562
cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Homo sapiens (human)	IC50 (µMol)	0.2863	0.0000	1.4651	10.0000	AID1406490; AID1720007; AID349551; AID349562
cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)	IC50 (µMol)	0.3270	0.0000	1.1463	10.0000	AID1406491; AID1720007; AID1902932; AID349551; AID349562
cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)	IC50 (µMol)	29,403.2000	0.0000	2.0724	10.0000	AID1756220; AID349549
High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A	Homo sapiens (human)	IC50 (µMol)	1,015.3650	0.0900	1.6310	4.6900	AID1756223; AID349563
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Homo sapiens (human)	IC50 (µMol)	71,000.0000	0.2300	1.9814	9.0000	AID1756217
cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)	IC50 (µMol)	32,003.2000	0.0003	1.9901	10.0000	AID1756219; AID349549
Beta-lactamase	Klebsiella pneumoniae	IC50 (µMol)	0.6700	0.6700	0.6700	0.6700	AID1758319
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)	IC50 (µMol)	97,600.0000	0.0000	1.4904	9.2000	AID1756224
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
heart valve development	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
ventricular septum development	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
aorta development	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
regulation of cGMP-mediated signaling	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
cAMP-mediated signaling	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
cGMP-mediated signaling	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
cellular response to macrophage colony-stimulating factor stimulus	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
negative regulation of vascular permeability	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
positive regulation of vascular permeability	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
regulation of cAMP-mediated signaling	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
cGMP catabolic process	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
positive regulation of inflammatory response	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
establishment of endothelial barrier	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
cellular response to mechanical stimulus	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
cellular response to cAMP	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
cellular response to cGMP	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
cellular response to 2,3,7,8-tetrachlorodibenzodioxine	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
positive regulation of gene expression	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
negative regulation of cGMP-mediated signaling	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
negative regulation of cAMP-mediated signaling	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
regulation of mitochondrion organization	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
positive regulation of cardiac muscle hypertrophy	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
regulation of nitric oxide mediated signal transduction	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
T cell proliferation	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
negative regulation of T cell proliferation	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
cGMP catabolic process	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
oocyte development	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
negative regulation of cardiac muscle contraction	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
relaxation of cardiac muscle	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
positive regulation of oocyte development	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
cAMP-mediated signaling	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
cAMP catabolic process	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
signal transduction	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
G protein-coupled receptor signaling pathway	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
sensory perception of smell	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
regulation of protein kinase A signaling	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
cellular response to xenobiotic stimulus	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
cAMP-mediated signaling	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
regulation of smooth muscle cell apoptotic process	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	Homo sapiens (human)
cGMP catabolic process	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	Homo sapiens (human)
regulation of smooth muscle cell proliferation	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	Homo sapiens (human)
cAMP-mediated signaling	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	Homo sapiens (human)
response to amphetamine	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
locomotory behavior	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
visual learning	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
monocyte differentiation	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
cellular response to macrophage colony-stimulating factor stimulus	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
dopamine catabolic process	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
serotonin metabolic process	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
cellular response to granulocyte macrophage colony-stimulating factor stimulus	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
cAMP-mediated signaling	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
neutrophil homeostasis	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
cAMP catabolic process	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
neutrophil chemotaxis	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
positive regulation of type II interferon production	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
positive regulation of interleukin-2 production	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
T cell receptor signaling pathway	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
leukocyte migration	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
cellular response to lipopolysaccharide	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
cellular response to xenobiotic stimulus	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
cellular response to epinephrine stimulus	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
negative regulation of adenylate cyclase-activating adrenergic receptor signaling pathway	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
regulation of cardiac muscle cell contraction	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
negative regulation of relaxation of cardiac muscle	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channel	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
cAMP-mediated signaling	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
cAMP catabolic process	cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Homo sapiens (human)
cAMP-mediated signaling	cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Homo sapiens (human)
regulation of heart rate	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
cAMP catabolic process	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
positive regulation of heart rate	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
positive regulation of type II interferon production	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
positive regulation of interleukin-2 production	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
positive regulation of interleukin-5 production	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
negative regulation of peptidyl-serine phosphorylation	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
negative regulation of heart contraction	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
T cell receptor signaling pathway	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
establishment of endothelial barrier	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
adrenergic receptor signaling pathway	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
regulation of cardiac muscle cell contraction	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
regulation of cell communication by electrical coupling involved in cardiac conduction	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
negative regulation of relaxation of cardiac muscle	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channel	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
cAMP-mediated signaling	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
angiogenesis	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
negative regulation of cell adhesion	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
G protein-coupled receptor signaling pathway	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
negative regulation of angiogenesis	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
cellular response to insulin stimulus	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
negative regulation of cell adhesion mediated by integrin	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
negative regulation of lipid catabolic process	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
cAMP-mediated signaling	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
cAMP catabolic process	High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A	Homo sapiens (human)
cAMP-mediated signaling	High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A	Homo sapiens (human)
cAMP-mediated signaling	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Homo sapiens (human)
oocyte maturation	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
lipid metabolic process	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
G protein-coupled receptor signaling pathway	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
response to xenobiotic stimulus	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
cAMP-mediated signaling	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
cGMP-mediated signaling	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
regulation of meiotic nuclear division	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
negative regulation of apoptotic process	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
negative regulation of vascular permeability	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
positive regulation of vascular permeability	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
steroid hormone mediated signaling pathway	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
negative regulation of cAMP-mediated signaling	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
positive regulation of oocyte development	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
regulation of ribonuclease activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
cellular response to cGMP	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
apoptotic signaling pathway	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
cAMP catabolic process	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)
cGMP catabolic process	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)
negative regulation of cGMP-mediated signaling	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)
cAMP-mediated signaling	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
magnesium ion binding	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activity	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
cGMP-stimulated cyclic-nucleotide phosphodiesterase activity	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
protein binding	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
zinc ion binding	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
cAMP binding	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
cGMP binding	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
TPR domain binding	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
phosphate ion binding	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
protein homodimerization activity	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activity	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activity	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
protein binding	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
cGMP binding	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
metal ion binding	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activity	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activity	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
protein binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
cAMP binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
metal ion binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
calmodulin-activated dual specificity 3',5'-cyclic-GMP, 3',5'-cyclic-AMP phosphodiesterase activity	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	Homo sapiens (human)
calmodulin binding	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	Homo sapiens (human)
metal ion binding	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	Homo sapiens (human)
calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activity	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
calmodulin-activated dual specificity 3',5'-cyclic-GMP, 3',5'-cyclic-AMP phosphodiesterase activity	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
protein binding	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
calmodulin binding	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
metal ion binding	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activity	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
calcium channel regulator activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
protein binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
cAMP binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
gamma-tubulin binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
transmembrane transporter binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
metal ion binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Homo sapiens (human)
metal ion binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Homo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
calcium channel regulator activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
protein binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
enzyme binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
signaling receptor regulator activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
cAMP binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
beta-2 adrenergic receptor binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
transmembrane transporter binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
metal ion binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
ATPase binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
scaffold protein binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
heterocyclic compound binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
cGMP-inhibited cyclic-nucleotide phosphodiesterase activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
protein binding	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
protein kinase B binding	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
metal ion binding	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activity	High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A	Homo sapiens (human)
metal ion binding	High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A	Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activity	High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A	Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activity	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Homo sapiens (human)
calmodulin-activated dual specificity 3',5'-cyclic-GMP, 3',5'-cyclic-AMP phosphodiesterase activity	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Homo sapiens (human)
calmodulin binding	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Homo sapiens (human)
metal ion binding	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activity	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Homo sapiens (human)
calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Homo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
cGMP-inhibited cyclic-nucleotide phosphodiesterase activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
protein binding	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
nuclear estrogen receptor activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
metal ion binding	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
estrogen binding	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activity	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)
cGMP-stimulated cyclic-nucleotide phosphodiesterase activity	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)
cAMP binding	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)
cGMP binding	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)
metal ion binding	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activity	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activity	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
nucleus	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
cytoplasm	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
mitochondrial outer membrane	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
mitochondrial inner membrane	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
endoplasmic reticulum	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
Golgi apparatus	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
cytosol	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
plasma membrane	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
presynaptic membrane	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
perinuclear region of cytoplasm	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
nucleus	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
mitochondrial inner membrane	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
perinuclear region of cytoplasm	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
mitochondrial outer membrane	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
synaptic membrane	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
cytosol	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
mitochondrial matrix	cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
cellular_component	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
cytosol	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
nucleoplasm	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
cytosol	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
plasma membrane	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
membrane	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
ruffle membrane	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
perinuclear region of cytoplasm	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
perinuclear region of cytoplasm	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
cytosol	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
nucleus	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
cytosol	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	Homo sapiens (human)
neuronal cell body	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
cytosol	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
neuronal cell body	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
centrosome	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
cytosol	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
synaptic vesicle	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
postsynaptic density	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
Z disc	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
dendritic spine	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
excitatory synapse	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
gamma-tubulin complex	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
voltage-gated calcium channel complex	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
nucleus	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
perinuclear region of cytoplasm	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
cytosol	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
extracellular space	cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Homo sapiens (human)
cytosol	cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Homo sapiens (human)
cilium	cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Homo sapiens (human)
cytosol	cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Homo sapiens (human)
nucleus	cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Homo sapiens (human)
perinuclear region of cytoplasm	cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Homo sapiens (human)
centrosome	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
cytosol	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
plasma membrane	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
apical plasma membrane	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
voltage-gated calcium channel complex	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
calcium channel complex	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
cytosol	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
nucleus	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
perinuclear region of cytoplasm	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
endoplasmic reticulum	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
Golgi apparatus	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
cytosol	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
membrane	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
guanyl-nucleotide exchange factor complex	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
cytosol	High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A	Homo sapiens (human)
perinuclear region of cytoplasm	High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A	Homo sapiens (human)
nucleus	High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A	Homo sapiens (human)
cytosol	High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A	Homo sapiens (human)
lysosome	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Homo sapiens (human)
cytosol	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Homo sapiens (human)
neuronal cell body	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Homo sapiens (human)
cytosol	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
membrane	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
cytosol	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
cytosol	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (94)

Assay ID	Title	Year	Journal	Article
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID349567	Antiinflammatory activity in human PBMC assessed as inhibition of IL4 release by FACS Array analysis	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID1756221	Inhibition of PDE4B (unknown origin)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID1756224	Inhibition of PDE10A (unknown origin)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID1406490	Inhibition of PDE4C1 (unknown origin)	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Lead-like Drugs: A Perspective.
AID349562	Inhibition of human recombinant PDE4 catalytic domain expressed in baculovirus-infected insect Sf9 cells by modified two-step method	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID1756191	Selectivity index, ratio of IC50 for PDE3B (unknown origin) to IC50 for PDE4B (unknown origin)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID1576707	Inhibition of serine hydrolase in HEK293T cell lysates at 50 uM preincubated for 30 mins followed by TAMRA-FP probe labeling for 20 mins by SDS-PAGE based ABPP analysis
AID1756214	Phototoxicity in albino guinea pig assessed as necrosis at 10 mg/kg topical treatment irradiated with 4.2 mw/cm2 UVA for 40 mins and measured after 24 hrs day of light irradiation by H and E staining based microscopic analysis	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID1576706	Inhibition of serine hydrolase in Escherichia coli Transetta (DE3) cell lysates at 50 uM preincubated for 30 mins followed by TAMRA-FP probe labeling for 20 mins by SDS-PAGE based ABPP analysis
AID1756219	Inhibition of PDE3A (unknown origin)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID349564	Antiinflammatory activity in mouse ear edema model assessed as inhibition of PMA-induced ear edema at 1 mg/ear administered 2 times 30 mins before and 15 mins after PMA challenge measured after 6 hrs of PMA application relative to control	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID349572	Inhibition of human recombinant PDE9 expressed in baculovirus-infected insect Sf9 cells at 10 uM by modified two-step method	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID349559	Antiinflammatory activity in human PBMC assessed as inhibition of phytohemagglutininin-induced IL10 release after 48 hrs by FACS Array analysis	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID349571	Inhibition of human recombinant PDE8 expressed in baculovirus-infected insect Sf9 cells at 10 uM by modified two-step method	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID1756215	Inhibition of PDE1A (unknown origin)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID349551	Inhibition of PDE4 in human U937 cells assessed as accumulation of [3H]adenosine by scintillation counting	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID1720007	Inhibition of PDE4 (unknown origin)	2020	Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19	Advances in the Development of Phosphodiesterase-4 Inhibitors.
AID1864430	Inhibition of NLRP3 inflammasome activation in LPS-primed mouse J774.A1 cells assessed as reduction in IL-1beta secretion at 1 uM	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel Oral Proteasome Inhibitor to Block NLRP3 Inflammasome Activation with Anti-inflammation Activity.
AID349563	Inhibition of human recombinant PDE7A1 expressed in baculovirus-infected insect Sf9 cells by modified two-step method	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID1756213	Phototoxicity in albino guinea pig assessed as infiltration of inflammatory cells at 10 mg/kg topical treatment irradiated with 4.2 mw/cm2 UVA for 40 mins and measured after 24 hrs day of light irradiation by H and E staining based microscopic analysis	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID1756195	Antiinflammatory activity against calcipotriol-induced atopic dermatitis mouse model assessed as swelling inhibition by measuring thickness of left ear at 30 mg/kg for 14 days (RVB = 0.26 +/- 0.01 mm)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID349552	Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha release in after 24 hrs by FACS Array analysis	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID1406489	Inhibition of PDE4B2 (unknown origin)	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Lead-like Drugs: A Perspective.
AID1756223	Inhibition of PDE7A (unknown origin)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID1756193	Selectivity index, ratio of IC50 for PDE7A (unknown origin) to IC50 for PDE4B (unknown origin)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID1756187	Selectivity index, ratio of IC50 for PDE1B (unknown origin) to IC50 for PDE4B (unknown origin)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID1756185	Antiinflammatory activity against PMA-induced ICR mouse ear oedema model assessed as reduction in ear swelling at 1 mg/ear topically administered and measured after 4 hrs	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID473469	Inhibition of PDE4	2010	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7	Design and synthesis of boron-containing PDE4 inhibitors using soft-drug strategy for potential dermatologic anti-inflammatory application.
AID349568	Inhibition of human recombinant PDE2 expressed in baculovirus-infected insect Sf9 cells at 10 uM by modified two-step method	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID1406491	Inhibition of PDE4D7 (unknown origin)	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Lead-like Drugs: A Perspective.
AID349549	Inhibition of human recombinant PDE3 catalytic domain expressed in baculovirus-infected insect Sf9 cells by modified two-step method	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID1756197	Antiinflammatory activity against calcipotriol-induced atopic dermatitis mouse model assessed as swelling inhibition at 30 mg/kg for 14 days	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID349561	Cytotoxicity against mouse L929 cells up to 100 uM	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID349550	Inhibition of human recombinant PDE1A3 expressed in baculovirus-infected insect Sf9 cells by modified two-step method	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID1756192	Selectivity index, ratio of IC50 for PDE5A (unknown origin) to IC50 for PDE4B (unknown origin)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID1756184	Inhibition of PDE4B (unknown origin) assessed as hydrolysis of [3H]-cGMP into [3H]-GMP incubated for 30 mins by scintillation of proximity assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID1902932	Inhibition of PDE4D (unknown origin)	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5	Discovery and Structural Optimization of Toddacoumalone Derivatives as Novel PDE4 Inhibitors for the Topical Treatment of Psoriasis.
AID349569	Inhibition of human recombinant PDE5 expressed in baculovirus-infected insect Sf9 cells at 10 uM by modified two-step method	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID349570	Inhibition of human recombinant PDE6 expressed in baculovirus-infected insect Sf9 cells at 10 uM by modified two-step method	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID1758319	Inhibition of Klebsiella pneumoniae KPC-2	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Discovery of 3-aryl substituted benzoxaboroles as broad-spectrum inhibitors of serine- and metallo-β-lactamases.
AID1406488	Inhibition of PDE4B1 (unknown origin)	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Lead-like Drugs: A Perspective.
AID349574	Inhibition of human recombinant PDE11 expressed in baculovirus-infected insect Sf9 cells at 10 uM by modified two-step method	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID349555	Antiinflammatory activity in human PBMC assessed as inhibition of phytohemagglutininin-induced IFN-gamma release after 24 hrs by FACSArray analysis	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID1756186	Selectivity index, ratio of IC50 for PDE1A (unknown origin) to IC50 for PDE4B (unknown origin)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID1756189	Selectivity index, ratio of IC50 for PDE2A (unknown origin) to IC50 for PDE4B (unknown origin)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID1756218	Inhibition of PDE2A (unknown origin)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID349573	Inhibition of human recombinant PDE10 expressed in baculovirus-infected insect Sf9 cells at 10 uM by modified two-step method	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID1406487	Inhibition of PDE4A1A (unknown origin)	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Lead-like Drugs: A Perspective.
AID349553	Antiinflammatory activity in human PBMC assessed as inhibition of phytohemagglutininin-induced IL2 release after 24 hrs by FACS Array analysis	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID1756216	Inhibition of PDE1B (unknown origin)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID1756194	Selectivity index, ratio of IC50 for PDE10A (unknown origin) to IC50 for PDE4B (unknown origin)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID1756196	Antiinflammatory activity against calcipotriol-induced atopic dermatitis mouse model assessed as swelling inhibition by measuring thickness of right ear at 30 mg/kg for 14 days (RVB = 0.55 +/- 0.06 mm)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID1756220	Inhibition of PDE3B (unknown origin)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID1756222	Inhibition of PDE5A (unknown origin)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID1756188	Selectivity index, ratio of IC50 for PDE1C (unknown origin) to IC50 for PDE4B (unknown origin)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID1756217	Inhibition of PDE1C (unknown origin)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID349557	Antiinflammatory activity in human PBMC assessed as inhibition of phytohemagglutininin-induced IL5 release after 48 hrs by FACS Array analysis	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID1756190	Selectivity index, ratio of IC50 for PDE3A (unknown origin) to IC50 for PDE4B (unknown origin)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID349566	Antiinflammatory activity in human PBMC assessed as inhibition of IL1-beta release by FACSArray analysis	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID1345234	Human phosphodiesterase 4B (Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs))	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID1345293	Human phosphodiesterase 7A (Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs))	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID1345271	Human phosphodiesterase 1A (Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs))	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (1.79)	29.6817
2010's	52 (46.43)	24.3611
2020's	58 (51.79)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	22 (18.49%)	5.53%
Reviews	34 (28.57%)	6.00%
Case Studies	12 (10.08%)	4.05%
Observational	0 (0.00%)	0.25%
Other	51 (42.86%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
histamine [no description available]	2.6	1	0	aralkylamino compound; imidazoles	human metabolite; mouse metabolite; neurotransmitter
propylene glycol Propylene Glycol: A clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.. propane-1,2-diol : The simplest member of the class of propane-1,2-diols, consisting of propane in which a hydrogen at position 1 and a hydrogen at position 2 are substituted by hydroxy groups. A colourless, viscous, hygroscopic, low-melting (-59degreeC) and high-boiling (188degreeC) liquid with low toxicity, it is used as a solvent, emulsifying agent, and antifreeze.	4.96	2	1	glycol; propane-1,2-diols	allergen; human xenobiotic metabolite; mouse metabolite; protic solvent
theophylline [no description available]	3.35	1	0	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
azathioprine Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed). azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.	5.85	3	0	aryl sulfide; C-nitro compound; imidazoles; thiopurine	antimetabolite; antineoplastic agent; carcinogenic agent; DNA synthesis inhibitor; hepatotoxic agent; immunosuppressive agent; prodrug
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	2.6	1	0	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
cilostazol [no description available]	2.05	1	0	lactam; tetrazoles	anticoagulant; bronchodilator agent; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; fibrin modulating drug; neuroprotective agent; platelet aggregation inhibitor; vasodilator agent
5,7-dimethoxycoumarin 5,7-dimethoxycoumarin: has photobiological activity	2.41	1	0	coumarins
etazolate Etazolate: A potent phosphodiesterase inhibitor proposed as an antipsychotic agent.. etazolate : A pyrazolopyridine that is 1H-pyrazolo[3,4-b]pyridine which is substituted at positions 1, 4, and 5 by ethyl, 2-isopropylidenehydrazino, and ethoxycarbonyl groups, respectively. A phosphodiesterase IV inhibitor with antidepressant and anxiolytic properties.	3.35	1	0	ethyl ester; hydrazone; pyrazolopyridine	alpha-secretase activator; antidepressant; antipsychotic agent; anxiolytic drug; GABA agent; neuroprotective agent; phosphodiesterase IV inhibitor
ibudilast [no description available]	3.35	1	0	pyrazolopyridine
methoxsalen Methoxsalen: A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA ADDUCTS in the presence of ultraviolet A irradiation.. methoxsalen : A member of the class of psoralens that is 7H-furo[3,2-g]chromen-7-one in which the 9 position is substituted by a methoxy group. It is a constituent of the fruits of Ammi majus. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered topically or orally in conjunction with UV-A for phototherapy treatment of vitiligo and severe psoriasis.	2.31	1	0	aromatic ether; psoralens	antineoplastic agent; cross-linking reagent; dermatologic drug; photosensitizing agent; plant metabolite
metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.	2.25	1	0	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
rolipram [no description available]	2.46	2	0	pyrrolidin-2-ones	antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
thalidomide Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.	4.69	4	0	phthalimides; piperidones
zardaverine zardaverine: structure given in first source. zardaverine : A pyridazinone derivative in which pyridazin-3(2H)-one is substituted at C-6 with a 4-(difluoromethoxy)-3-methoxyphenyl group. It is a phosphodiesterase inhibitor, selective for PDE3 and 4.	3.35	1	0	organofluorine compound; pyridazinone	anti-asthmatic drug; bronchodilator agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; peripheral nervous system drug
boranes Boranes: The collective name for the boron hydrides, which are analogous to the alkanes and silanes. Numerous boranes are known. Some have high calorific values and are used in high-energy fuels. (From Grant & Hackh's Chemical Dictionary, 5th ed). borane : The simplest borane, consisting of a single boron atom carrying three hydrogens.. boranes : The molecular hydrides of boron.	2.08	1	0	boranes; mononuclear parent hydride
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	3.68	2	0	pyrrole; secondary amine
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	4.8	3	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	2.31	1	0	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiazoles [no description available]	2.31	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
alpha-aminopyridine alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.	4.59	3	0
methotrexate [no description available]	5.85	3	0	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
cilomilast [no description available]	3.35	1	0	methoxybenzenes
rp 73401 piclamilast: an antiasthmatic agent and phosphodiesterase 4 inhibitor; structure in first source. piclamilast : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 3-(cyclopentyloxy)-4-methoxybenzoic acid with the primary amino group of 3,5-dichloropyridin-4-amine.	3.35	1	0	aromatic ether; benzamides; chloropyridine; monocarboxylic acid amide	anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; phosphodiesterase IV inhibitor
8-methoxymethyl-3-isobutyl-1-methylxanthine 8-methoxymethyl-3-isobutyl-1-methylxanthine: inhibitor of phosphodiesterase I	2.05	1	0	oxopurine
mesembrenone mesembrenone: a psychoactive compound isolated from Sceletium tortuosum; structure in first source	3.35	1	0	pyrrolidines
bortezomib [no description available]	3.78	2	0	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
meropenem Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.	2.31	1	0	alpha,beta-unsaturated monocarboxylic acid; carbapenemcarboxylic acid; organic sulfide; pyrrolidinecarboxamide	antibacterial agent; antibacterial drug; drug allergen
tacrolimus Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.	4.11	3	0	macrolide lactam	bacterial metabolite; immunosuppressive agent
mycophenolic acid Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.	2.15	1	0	2-benzofurans; gamma-lactone; monocarboxylic acid; phenols	anticoronaviral agent; antimicrobial agent; antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; environmental contaminant; immunosuppressive agent; mycotoxin; Penicillium metabolite; xenobiotic
roflumilast [no description available]	5.34	5	0	aromatic ether; benzamides; chloropyridine; cyclopropanes; organofluorine compound	anti-asthmatic drug; phosphodiesterase IV inhibitor
stilbenes Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.	4.91	3	0	stilbene
amygdalin [no description available]	3.51	1	0
capsaicin ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.	2.6	1	0	capsaicinoid	non-narcotic analgesic; TRPV1 agonist; voltage-gated sodium channel blocker
oxazolone Oxazolone: Immunologic adjuvant and sensitizing agent.	2.31	1	0
3-(n,n-dimethylsulfonamido)-4-methyl-nitrobenzene BRL-50481 : A C-nitro compound that is benzene substituted by N,N-dimethylaminosulfonyl, methyl and nitro groups at positions 1, 2 and 5, respectively. It is a phosphodiesterase inhibitor selective for the PDE7 subtype (Ki = 180 nM).	2.05	1	0	C-nitro compound; sulfonamide; toluenes	bone density conservation agent; EC 3.1.4.53 (3',5'-cyclic-AMP phosphodiesterase) inhibitor; geroprotector
tetomilast [no description available]	3.35	1	0
calcipotriene [no description available]	2.41	1	0	cyclopropanes; hydroxy seco-steroid; seco-cholestane; secondary alcohol; triol	antipsoriatic; drug allergen
gsk 256066 [no description available]	3.35	1	0
avibactam avibactam : A member of the class of azabicycloalkanes that is (2S,5R)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide in which the amino hydrogen at position 6 is replaced by a sulfooxy group. Used (in the form of its sodium salt) in combination with ceftazidime pentahydrate for the treatment of complicated urinary tract infections including pyelonephritis.	2.31	1	0	azabicycloalkane; hydroxylamine O-sulfonic acid; monocarboxylic acid amide; ureas	antibacterial drug; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor
mcc-950 [no description available]	2.41	1	0
tofacitinib tofacitinib : A pyrrolopyrimidine that is pyrrolo[2,3-d]pyrimidine substituted at position 4 by an N-methyl,N-(1-cyanoacetyl-4-methylpiperidin-3-yl)amino moiety. Used as its citrate salt to treat moderately to severely active rheumatoid arthritis.	4.52	3	0	N-acylpiperidine; nitrile; pyrrolopyrimidine; tertiary amino compound	antirheumatic drug; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
rpl 554 ensifentrine: a phosphodiesterase 3/4 inhibitor; structure in first source	3.35	1	0
tavaborole tavaborole: has antifungal activity; structure in first source. tavaborole : A member of the class of benzoxaboroles that is 1,3-dihydro-1-hydroxy-2,1-benzoxaborole substituted at position 5 by a fluoro group. A topical antifungal agent used for the treatment of onychomycosis (fungal infection of the toenails and fingernails).	3.97	3	0	benzoxaborole; organofluorine compound	antifungal agent; EC 6.1.1.4 (leucine--tRNA ligase) inhibitor; protein synthesis inhibitor
apremilast [no description available]	5.22	5	0	aromatic ether; N-acetylarylamine; phthalimides; sulfone	non-steroidal anti-inflammatory drug; phosphodiesterase IV inhibitor
sodium hypochlorite Sodium Hypochlorite: It is used as an oxidizing and bleaching agent and as a disinfectant. (From Grant & Hackh's Chemical Dictionary, 5th ed). sodium hypochlorite : An inorganic sodium salt in which hypochlorite is the counterion. It is used as a bleaching and disinfecting agent and is commonly found in household bleach.	3.31	1	0	inorganic sodium salt	bleaching agent; disinfectant
incb-018424 [no description available]	4.33	2	0	nitrile; pyrazoles; pyrrolopyrimidine	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
ixazomib ixazomib: a proteasome inhibitor with antineoplastic activity; MLN2238 is the biologically active form of MLN9708; structure in first source. ixazomib : A glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma.	2.41	1	0	benzamides; boronic acids; dichlorobenzene; glycine derivative	antineoplastic agent; apoptosis inducer; drug metabolite; orphan drug; proteasome inhibitor
piperidines Piperidines: A family of hexahydropyridines.	4.52	3	0
interleukin-8 Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.	2.25	1	0
delgocitinib delgocitinib: a Janus kinase inhibitor. delgocitinib : A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine substituted by a (3S,4R)-1-(cyanoacetyl)-3-methyl-1,6-diazaspiro[3.4]octan-6-yl group at position 4. It is a pan-Janus kinase (JAK) inhibitor and is approved for treatment of atopic dermatitis (AD) in Japan.	3.31	1	0	azaspiro compound; N-acylazetidine; nitrile; pyrrolopyrimidine; tertiary amino compound; tertiary carboxamide	anti-inflammatory drug; antipsoriatic; antiseborrheic; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
rpx7009 RPX7009: a beta-lactamase inhibitor; structure in first source	2.41	1	0
chf6001 tanimilast: a phosphodiesterase-4 inhibitor; structure in first source	3.35	1	0
cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	3.69	2	0

Condition	Indicated	Relationship Strength	Studies	Trials
Eczema, Atopic [description not available]	0	19.47	118	48
Anasarca [description not available]	0	2.78	3	0
Palmoplantaris Pustulosis [description not available]	0	9.28	18	2
Dermatitis, Atopic A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.	1	21.47	118	48
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	0	2.78	3	0
Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.	1	11.28	18	2
Emesis [description not available]	0	3.17	1	0
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	0	3.17	1	0
Congenital Zika Syndrome [description not available]	0	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	3.97	8	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	0	2.25	1	0
Allergic Rhinitis [description not available]	0	2.31	1	0
Asthma, Bronchial [description not available]	0	2.31	1	0
Allergy, Food [description not available]	0	2.31	1	0
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	0	2.31	1	0
Food Hypersensitivity Gastrointestinal disturbances, skin eruptions, or shock due to allergic reactions to allergens in food.	0	2.31	1	0
Rhinitis, Allergic An inflammation of the NASAL MUCOSA triggered by ALLERGENS.	0	2.31	1	0
Hypermelanosis [description not available]	0	2.41	1	0
Prurigo A name applied to several itchy skin eruptions of unknown cause. The characteristic course is the formation of a dome-shaped papule with a small transient vesicle on top, followed by crusting over or lichenification. (From Dorland, 27th ed)	0	2.41	1	0
Hyperpigmentation Excessive pigmentation of the skin, usually as a result of increased epidermal or dermal melanin pigmentation, hypermelanosis. Hyperpigmentation can be localized or generalized. The condition may arise from exposure to light, chemicals or other substances, or from a primary metabolic imbalance.	0	2.41	1	0
Balanitis Inflammation of the head of the PENIS, glans penis.	0	2.6	1	0
Erythema Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.	0	2.41	1	0
Lichen Ruber Planus [description not available]	0	2.41	1	0
Lichen Planus An inflammatory, pruritic disease of the skin and mucous membranes, which can be either generalized or localized. It is characterized by distinctive purplish, flat-topped papules having a predilection for the trunk and flexor surfaces. The lesions may be discrete or coalesce to form plaques. Histologically, there is a saw-tooth pattern of epidermal hyperplasia and vacuolar alteration of the basal layer of the epidermis along with an intense upper dermal inflammatory infiltrate composed predominantly of T-cells. Etiology is unknown.	0	2.41	1	0
Hirsutism A condition observed in WOMEN and CHILDREN when there is excess coarse body hair of an adult male distribution pattern, such as facial and chest areas. It is the result of elevated ANDROGENS from the OVARIES, the ADRENAL GLANDS, or exogenous sources. The concept does not include HYPERTRICHOSIS, which is an androgen-independent excessive hair growth.	0	2.6	1	0
Hypertrichosis Excessive hair growth at inappropriate locations, such as on the extremities, the head, and the back. It is caused by genetic or acquired factors, and is an androgen-independent process. This concept does not include HIRSUTISM which is an androgen-dependent excess hair growth in WOMEN and CHILDREN.	0	2.6	1	0
Innate Inflammatory Response [description not available]	0	4.89	6	0
Itching [description not available]	0	14.95	37	29
Infections, Staphylococcal [description not available]	0	3.52	4	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	4.89	6	0
Pruritus An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.	0	14.95	37	29
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	0	3.52	4	0
Vitiligo A disorder consisting of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck, and in skin folds. Age of onset is often in young adulthood and the condition tends to progress gradually with lesions enlarging and extending until a quiescent state is reached.	1	4.6	1	0
Leukokeratosis Leukoplakic lesions related to abnormal keratin fiber formation.	0	3.99	1	1
Leukoplakia A white patch lesion found on a MUCOUS MEMBRANE that cannot be scraped off. Leukoplakia is generally considered a precancerous condition, however its appearance may also result from a variety of HEREDITARY DISEASES.	0	3.99	1	1
Dermatosclerosis [description not available]	0	3.99	1	1
Scleroderma, Localized A term used to describe a variety of localized asymmetrical SKIN thickening that is similar to those of SYSTEMIC SCLERODERMA but without the disease features in the multiple internal organs and BLOOD VESSELS. Lesions may be characterized as patches or plaques (morphea), bands (linear), or nodules.	1	5.99	1	1
Chronic Illness [description not available]	0	8.58	5	1
Dermatitis, Eczematous [description not available]	0	6.69	5	2
Dermatoses [description not available]	0	6.53	4	2
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	0	8.58	5	1
Eczema A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).	1	8.69	5	2
Skin Diseases Diseases involving the DERMIS or EPIDERMIS.	0	6.53	4	2
Allergic Contact Dermatitis [description not available]	0	3.74	2	0
Dermatitis, Allergic Contact A contact dermatitis due to allergic sensitization to various substances. These substances subsequently produce inflammatory reactions in the skin of those who have acquired hypersensitivity to them as a result of prior exposure.	0	3.74	2	0
Ache [description not available]	0	6.25	6	1
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	0	6.25	6	1
Kahler Disease [description not available]	0	3.55	2	0
Necrobiotic Xanthogranuloma A cutaneous necrobiotic disorder characterized by firm, yellow plaques or nodules, often in a periorbital distribution. It is often accompanied by an elevated ERYTHROCYTE SEDIMENTATION RATE; LEUKOPENIA; and MONOCLONAL GAMMOPATHY (IgG-kappa type) and systemic involvement.	0	2.25	1	0
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	0	3.55	2	0
Disease Exacerbation [description not available]	0	4.02	4	0
Dermatitis, Periocular [description not available]	0	2.25	1	0
Dermatitis, Perioral A papular eruption of unknown etiology that progresses to residual papular erythema and scaling usually confined to the area of the mouth, and almost exclusively occurring in young women. It may also be localized or extend to involve the eyelids and adjacent glabella area of the forehead (periocular dermatitis). (Dorland, 28th ed)	0	2.25	1	0
Dermatitis Seborrheica [description not available]	0	2.61	2	0
Dermatitis, Seborrheic A chronic inflammatory disease of the skin with unknown etiology. It is characterized by moderate ERYTHEMA, dry, moist, or greasy (SEBACEOUS GLAND) scaling and yellow crusted patches on various areas, especially the scalp, that exfoliate as dandruff. Seborrheic dermatitis is common in children and adolescents with HIV INFECTIONS.	0	2.61	2	0
Lichen Simplex Chronicus [description not available]	0	2.31	1	0
Neurodermatitis An extremely variable eczematous skin disease that is presumed to be a response to prolonged vigorous scratching, rubbing, or pinching to relieve intense pruritus. It varies in intensity, severity, course, and morphologic expression in different individuals. Neurodermatitis is believed by some to be psychogenic. The circumscribed or localized form is often referred to as lichen simplex chronicus.	0	2.31	1	0
Nail Fungus [description not available]	0	4.02	2	0
Onychomycosis A fungal infection of the nail, usually caused by DERMATOPHYTES; YEASTS; or nondermatophyte MOLDS.	0	4.02	2	0
Acute Symptom Flare [description not available]	0	2.15	1	0
Infection [description not available]	0	2.15	1	0
Infections Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.	0	2.15	1	0
Genetic Predisposition [description not available]	0	6.98	4	0
Hives [description not available]	0	6.98	4	0
Urticaria A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability. The causative mechanism may be allergy, infection, or stress.	0	6.98	4	0
Hand Dermatosis [description not available]	0	2.17	1	0
Foot Dermatoses Skin diseases of the foot, general or unspecified.	0	2.17	1	0
Hand Dermatoses Skin diseases involving the HANDS.	0	2.17	1	0
Allergy, Peanut [description not available]	0	3.12	1	0
Peanut Hypersensitivity Allergic reaction to peanuts that is triggered by the immune system.	0	3.12	1	0
Feuerstein-Mims Syndrome [description not available]	0	2.21	1	0
Facial Dermatoses Skin diseases involving the FACE.	0	3.64	1	1
Pink Eye [description not available]	0	2.25	1	0
Dry Eye [description not available]	0	2.25	1	0
Conjunctivitis INFLAMMATION of the CONJUNCTIVA.	0	2.25	1	0
Keratitis Inflammation of the cornea.	0	2.25	1	0
Dry Eye Syndromes Corneal and conjunctival dryness due to deficient tear production, predominantly in menopausal and post-menopausal women. Filamentary keratitis or erosion of the conjunctival and corneal epithelium may be caused by these disorders. Sensation of the presence of a foreign body in the eye and burning of the eyes may occur.	0	2.25	1	0

an2728

Description

Cross-References

Synonyms (74)

Research Excerpts

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (3)

Protein Targets (18)

Potency Measurements

Inhibition Measurements

Biological Processes (83)

Molecular Functions (29)

Ceullar Components (32)

Bioassays (94)

Research

Studies (112)

Market Indicators

Research Demand Index: 19.14

Study Types

an2728

Description

Cross-References

Synonyms (74)

Research Excerpts

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (3)

Protein Targets (18)

Potency Measurements

Inhibition Measurements

Biological Processes (83)

Molecular Functions (29)

Ceullar Components (32)

Bioassays (94)

Research

Studies (112)

Market Indicators

Research Demand Index: 19.14

Study Types

Related Drugs (53)

Related Conditions (77)